SynthesisInternational braz j urol : official journal of the Brazilian Society of Urology
Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis.
Synthesis in International braz j urol : official journal of the Brazilian Society of Urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Darifenacin Versus Parasacral Transcutaneous Electric Nerve stimulation for overactive bladder syndrome in patients infected with Human T-Lymphotropic Virus 1 - randomized open clinical trial.International braz j urol : official journal of the Brazilian Society of UrologyTrial
- Efficacy and Safety of Mirabegron Compared to Solifenacin in Treatment of Non-neurogenic Overactive Bladder in Children: A Randomized Controlled Trial.International braz j urol : official journal of the Brazilian Society of UrologyTrial
- Mirabegron for overactive bladder.Canadian family physician Medecin de famille canadien · 2026Article
- Long-term efficacy and safety of solifenacin, mirabegron, and their combination for overactive bladder: a systematic review.Frontiers in pharmacology · 2026Review
- Efficacy of Mirabegron and Propiverine Combination in the Treatment of Refractory Overactive Bladder.International urogynecology journal · 2025Article
- Comparative efficacy and adverse effects of β3-agonists and antimuscarinics in overactive bladder: a network and component network meta-analysis.European journal of clinical pharmacology · 2025Article
- Drug-induced xerostomia and hyposalivation in patients with overactive bladder: a prospective open-label observational study comparing antimuscarinics and β3-adrenoceptor agonists.Scientific reports · 2025Observational
- Update on the Treatment of Autonomic Disorders.Current treatment options in neurology · 2025Article
- Higher skin sympathetic nerve activity as a potential predictor of overactive bladder in females refractory to oral monotherapy.The Kaohsiung journal of medical sciences · 2024Article
- Article
- Article
- International Brazilian Journal of Urology is among the Top 10 urologic journals - the new Impact Facto is 3.7!International braz j urol : official journal of the Brazilian Society of UrologyArticle
- International Brazilian of Urology is the Seventh Biggest Impact Factor (4.5) Among Urology and Andrology Journals in the World.International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
bladder based on a systematic review and network meta-analysis approach.
methodsPubmed, Embase, Web of Science, and the Cochrane Register of Clinical Trials databases were systematically searched. The search time frame was from database creation to June 2, 2022. Randomized controlled double-blind trials of oral medication for overactive bladder were screened against the protocol's entry criteria. Trials were evaluated for quality using the Cochrane Risk of Bias Assessment Tool, and data were statistically analyzed using Stata 16.0 software.
resultA total of 60 randomized controlled double-blind clinical trials were included involving 50,333 subjects. Solifenacin 10mg was the most effective in mean daily micturitions and incontinence episodes, solifenacin 5/10mg in mean daily urinary urgency episodes and nocturia episodes, fesoterodine 8mg in urgency incontinence episodes/d and oxybutynin 5mg in voided volume/micturition. In terms of safety, solifenacin 5mg, ER-tolterodine 4mg, mirabegron, vibegron and ER-oxybutynin 10mg all showed a better incidence of dry mouth, fesoterodine 4mg, ER-oxybutynin 10mg, tolterodine 2mg, and vibegron in the incidence of constipation. Compared to placebo, imidafenacin 0.1mg showed a significantly increased incidence in hypertension, solifenacin 10mg in urinary tract infection, fesoterodine 4/8mg and darifenacin 15mg in headache.
conclusionSolifenacin showed better efficacy. For safety, most anticholinergic drugs were more likely to cause dry mouth and constipation, lower doses were better tolerated. The choice of drugs should be tailored to the patient's specific situation to find the best balance between efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.